Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) saw unusually-high trading volume on Tuesday. 184,380 shares traded hands during trading, an increase of 216% from the average daily volume of 58,320 shares. The stock last traded at $66.1020 and had previously closed at $68.58.
Novozymes A/S Stock Performance
The business’s fifty day simple moving average is $67.43 and its 200-day simple moving average is $62.68. The firm has a market cap of $27.44 billion, a P/E ratio of 39.17, a price-to-earnings-growth ratio of 3.08 and a beta of 0.86. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 0.25.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.26). The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%. As a group, sell-side analysts expect that Novozymes A/S will post 2.45 earnings per share for the current year.
Institutional Investors Weigh In On Novozymes A/S
An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B grew its holdings in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,900 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
About Novozymes A/S
Novozymes A/S was a Denmark-based biotechnology company that developed and produced enzymes and microorganisms for industrial and consumer applications. Its solutions were used in areas including household care, food and beverages, agriculture, animal health and bioenergy. The company’s products included enzymes used in detergents, baking, brewing and biofuel production, as well as microbial solutions for agricultural and other industrial processes. Novozymes served customers in markets around the world.
See Also
- Five stocks we like better than Novozymes A/S
- Microsoft’s Neocloud Pullback Isn’t a Crack in AI Demand
- Fox’s $22 Billion Roku Acquisition Reshapes Its Streaming Business
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
